Can New Combo Fill ‘Unmet Need’ in R/R Hodgkin Lymphoma?
Acimtamig, a first-in-class CD3src/CD16A bispecific innate cell engager (ICE), combined with an off-the-shelf cord-blood-derived natural killer cell product (AlloNK), shows...
Acimtamig, a first-in-class CD3src/CD16A bispecific innate cell engager (ICE), combined with an off-the-shelf cord-blood-derived natural killer cell product (AlloNK), shows...